Revival and Recharacterization of a Preclinical Model of Hormone-Dependent Breast Cancer to Study Immunotherapy
- 11 May 2022
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (6), 672-673
- https://doi.org/10.1158/2326-6066.cir-22-0315
Abstract
Immune checkpoint inhibitors have yet to significantly improve outcomes for hormone-dependent estrogen/progesterone receptor–positive breast cancer. To address this issue, there is a need for murine models that more closely mimic hormone receptor–positive breast cancer. In this issue, Gil Del Alcazar and colleagues provide an in-depth characterization of a Nitroso-N-methylurea–induced mammary tumor model in outbred Sprague-Dawley rats that meets these needs as it mimics the heterogeneity for mutational profiles, estrogen receptor expression, and immune evasive mechanisms observed in human breast cancer. See related article by Gil Del Alcazar et al., (1).Keywords
This publication has 5 references indexed in Scilit:
- Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast CancerCancer Immunology Research, 2022
- Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor MicroenvironmentCancer Immunology Research, 2022
- Prevalence and mutational determinants of high tumor mutation burden in breast cancerAnnals of Oncology, 2020
- Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of TumorsCancer Cell, 2017
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013